Replimune reported a fiscal third-quarter net loss as it continued to invest heavily in clinical development and commercial readiness for RP1 ahead of a potential regulatory decision.

Replimune reported a net loss of $74.1 million for the fiscal fourth quarter of 2025, compared to a net loss of $55.1 million in the same period last year. The company's cash position increased to $483.8 million, driven by a public offering. Research and development expenses rose due to scaling operations for the commercial launch of RP1.

Replimune reported significant regulatory milestones for RP1 in anti-PD-1 failed melanoma, with the FDA accepting the BLA for RP1 plus nivolumab in advanced melanoma for priority review and setting a PDUFA date of July 22, 2025. The company is focused on ensuring a successful commercial launch of RP1 upon approval and is well-capitalized with over $500 million in cash to execute its plans.

Replimune Group, Inc. announced financial results for the fiscal second quarter ended September 30, 2024. The company believes that existing cash, cash equivalents and short-term investments, as of September 30, 2024 will enable the Company to fund operations into the second half of 2026.

Replimune Group, Inc. announced financial results for the fiscal first quarter ended June 30, 2024. The company is gearing up for a pre-BLA meeting with the FDA and preparing to enroll the first patient in their confirmatory trial of RP1 in anti-PD1 failed melanoma.

Replimune announced financial results for the fiscal fourth quarter and year ended March 31, 2024. The company believes that existing cash, cash equivalents and short-term investments, as of March 31, 2024 will enable the Company to fund operations into the second half of 2026.

Replimune's existing cash, cash equivalents and short-term investments, as of December 31, 2023, will enable the Company to fund operations into the second half of 2026.

Replimune Group, Inc. reported financial results for the fiscal second quarter ended September 30, 2023. The company is planning to present topline data from the CERPASS clinical trial and an initial snapshot from the IGNYTE clinical trial cohort. They are also excited to present the design of a confirmatory study agreed with the FDA to support a potential approval of RP1 in anti-PD1 failed melanoma via the accelerated approval pathway.

Replimune reported its fiscal first quarter 2024 financial results, highlighting positive updates for RP1 in anti-PD1 failed melanoma and RP2 in uveal melanoma presented at ASCO. Top-line data from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo in cutaneous squamous cell carcinoma is expected in early Q4 2023, and a BLA submission is anticipated in Q1/2 2024. A cost-sharing collaboration in cutaneous squamous cell carcinoma in the neoadjuvant setting was entered into with Incyte.

Replimune Group, Inc. announced financial results for the fiscal fourth quarter and year ended March 31, 2023. The company is focused on topline data from the CERPASS clinical trial of RP1 combined with Libtayo® in CSCC, expected in the next quarter, and plans to provide an initial data snapshot from the full IGNYTE anti-PD1 failed melanoma cohort by year-end.

Replimune reported its Q3 financial results, highlighting a strengthened balance sheet with $259 million raised through a public offering, extending the cash runway into H2 2025. Key clinical trial milestones were achieved, including target enrollment in the IGNYTE trial and anticipation of topline data from the CERPASS trial in Q3 2023.

Replimune Group announced financial results for the fiscal second quarter ended September 30, 2022. The company is focused on establishing oncolytic immunotherapies as a cornerstone treatment for solid tumor indications and plans to establish a major skin cancer franchise with RP1. They completed a $200 million term-loan that extended cash runway into 2025.

Replimune announced that the target enrollment of 180 patients was reached in the CERPASS trial and the first 75 patients were enrolled in the IGNYTE clinical trial. They also believe that existing cash, cash equivalents and short-term investments will fund operating expenses and capital expenditure requirements into the second half of 2024.

Replimune reported their Q4 2022 financial results and corporate update, ending the fiscal year in a strong position. They are maintaining guidance to complete enrollment into the CERPASS clinical trial in CSCC mid-year and to release top line data in early 2023. Initial directional data from the IGNYTE clinical trial in anti-PD1 failed melanoma is expected in late 2022.

Replimune Group Inc. reported financial results for the fiscal third quarter ended December 31, 2021, and provided a business update, highlighting upcoming milestones and data presentations.

Replimune reported its financial results for the second fiscal quarter ended September 30, 2021. The company believes that existing cash and cash equivalents will fund operating expenses and capital expenditure requirements into the second half of 2024.

Replimune reported its fiscal first quarter financial results, highlighting the continued demonstration of depth and durability of responses observed with RP1 and RP2. The company expects to complete accrual in its registration directed CERPASS study in CSCC and in its registration directed cohort of patients with anti-PD-1 failed melanoma mid next year. They are designing a comprehensive development plan with the goal of establishing their product candidates as a cornerstone of cancer treatment regimens, including in patients with liver metastases.

Replimune reported its fiscal fourth-quarter and year-end 2021 financial results. The company is advancing its clinical programs and expects data updates in June. They ended the year with approximately $476 million in cash, which is expected to fund operations into the second half of 2024.

Replimune Group Inc. announced financial results for the fiscal third quarter ended December 31, 2020, and provided a business update, highlighting the commencement of dosing with RP3 and continued enrollment in registration-directed clinical trials with RP1.

Replimune Group, Inc. announced financial results for the fiscal second quarter ended September 30, 2020, and provided a business update. The company released clinical data with RP2, demonstrating durable single agent responses in heavily pre-treated patients. Updated data for RP1 in combination with Opdivo in melanoma and non-melanoma skin cancers continues to improve upon the recent June update. The company closed on an offering of common stock and pre-funded warrants raising approximately $287 million.

Replimune Group, Inc. reported financial results for the fiscal first quarter ended June 30, 2020. Clinical proof of principle was established with RP1 in combination with Opdivo for immune-responsive tumors, supporting registration-directed development in CSCC and anti-PD1 refractory melanoma. The company raised gross proceeds of $115 million through a public offering, extending the cash runway to mid-2023.

Replimune Group, Inc. announced its financial results for the fiscal fourth quarter and year ended March 31, 2020. The company is focused on developing oncolytic immuno-gene therapies and plans to initiate clinical development of RP1 in anti-PD1 refractory patients with non-small cell lung cancer (NSCLC).